OakChart

Lexeo Therapeutics Inc

LXEOHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.07+0.01 (0.33%)
2026-11-11 22:33 CET
Market cap
251.19 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-87.27 USD m
Free cash flow, TTM
-88.70 USD m
EPS diluted, TTM
-1.16
P/E
-
Compare

Price

LXEO against its 20, 50 and 200-day averages
2050200beat
4.006.003.3M6.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26LXEOclose 3.0720-day 2.9650-day 3.46200-day 5.043.0752w low

72.1% under the 52-week high of 10.99 on 23 Dec 2025. 52-week low 2.55 on 19 Oct 2026. Last 15 sessions, 29.8% high to low

Volume 0.40× normal · the line is the 50-bar volume average

Profile

LXEO
52-week range, 6% of the way up
2.5510.99

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer's disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

IndexRUT
Employees59
IPONov 03, 2023
Beta1.63
ATR, 14d0.29
Rel volume0.40
Short float24.66%
Insider own15.83%
Inst own97.41%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap252.01M
Enterprise Value47.12M
Income-87.27M
Sales0.00M
Book/sh2.99
Cash/sh2.58
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees59
IPONov 03, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.03
P/C1.19
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio13.89
Current Ratio13.89
Debt/Eq0.03
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.16
EPS next Y-1.34
EPS next Q-0.32
EPS this Y36.08%
EPS next Y-12.34%
EPS next 5Y13.49%
EPS past 3/5Y5.73% -57.31%
Sales past 3/5Y- -
EPS Y/Y TTM64.51%
Sales Y/Y TTM-
EPS Q/Q49.57%
Sales Q/Q-
EarningsAug 12 BMO
EPS/Sales Surpr.-5.19% -

Ownership

Insider Own15.83%
Insider Trans-0.54%
Inst Own97.41%
Inst Trans7.38%
ROA-40.50%
ROE-46.76%
ROIC-36.48%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA203.65%
SMA50-11.17%
SMA200-39.03%
Trades-

Technical

Shs Outstand78.62M
Shs Float69.09M
Short Float24.66%
Short Ratio12.82
Short Interest17.04M
52W High10.99 -72.07%
52W Low2.55 20.39%
Volatility13.59% 10.43%
ATR (14)0.29
RSI (14)47.96
Beta1.63
Rel Volume0.40
Avg Volume1.33M
Volume527,431

Performance

Perf Week-4.95%
Perf Month12.04%
Perf Quarter-38.10%
Perf Half Y-46.70%
Perf YTD-69.08%
Perf Year-66.34%
Perf 3Y-71.52%
Perf 5Y-
Perf 10Y-
Recom1.11
Target Price20.67
Prev Close3.06
Price3.07
Change %0.33%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Dec 18, 2025InitiatedRRaymond JamesStrong Buy$25+714.3%
Nov 20, 2025InitiatedCCantor FitzgeraldOverweight$19+518.9%
Oct 15, 2025InitiatedGGuggenheimBuy$30+877.2%
Jul 31, 2025InitiatedOOppenheimerOutperform$20+551.5%
Jun 13, 2024InitiatedRRobert W. BairdOutperform$28+812.1%
Jun 06, 2024InitiatedHH.C. WainwrightBuy$22+616.6%
Nov 28, 2023InitiatedSStifelBuy$20+551.5%
Nov 28, 2023InitiatedRRBC Capital MktsOutperform$22+616.6%
Nov 28, 2023InitiatedLLeerink PartnersOutperform$19+518.9%
Nov 28, 2023InitiatedJJP MorganOverweight$20+551.5%

Peers

Mkt cap
TickerCompanyMkt cap
TNYATenaya Therapeutics Inc84.61M
RCKTRocket Pharmaceuticals Inc272.24M
RNAAtrium Therapeutics Inc177.32M
LRMRLarimar Therapeutics Inc283.61M
DSGNDesign Therapeutics Inc689.67M
RGNXRegenxbio Inc560.06M
SLDBSolid Biosciences Inc848.24M
QUREuniQure NV1.72B
FDMT4D Molecular Therapeutics Inc717.62M
TSHATaysha Gene Therapies Inc1.39B

Insider trading

latest 14 of 37
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Tamayo Louis EdwardChief Financial OfficerAug 18 '26Sale4.914,11720,20392,907Aug 19 05:00 PM
Townsend Richard NolanChief Executive OfficerAug 18 '26Sale4.953,34516,562374,472Aug 19 05:00 PM
Otero Jose ManuelChief Operating OfficerAug 18 '26Sale4.961,3046,464136,178Aug 19 05:00 PM
Townsend Richard NolanOfficerAug 18 '26Proposed Sale4.953,34516,562Aug 18 03:16 PM
Otero Jose ManuelOfficerAug 18 '26Proposed Sale4.961,3046,464Aug 18 03:12 PM
Tamayo Louis EdwardOfficerAug 18 '26Proposed Sale4.914,11720,203Aug 18 03:09 PM
Tamayo Louis EdwardChief Financial OfficerJul 01 '26Sale4.494,64120,83897,024Jul 01 06:49 PM
Otero Jose ManuelChief Operating OfficerJul 01 '26Sale4.484,66620,904137,482Jul 01 06:49 PM
Bhalla Narinder PalChief Medical OfficerJul 01 '26Sale4.4222,30698,59382,194Jul 01 06:48 PM
Townsend Richard NolanChief Executive OfficerJul 01 '26Sale4.4825,947116,243377,817Jul 01 06:47 PM
Otero Jose ManuelOfficerJul 01 '26Proposed Sale4.484,66620,919Jul 01 04:54 PM
Tamayo Louis EdwardOfficerJul 01 '26Proposed Sale4.494,64120,815Jul 01 04:43 PM
Bhalla Narinder PalOfficerJul 01 '26Proposed Sale4.4222,30698,684Jul 01 04:43 PM
Townsend Richard NolanOfficerJul 01 '26Proposed Sale4.4825,947116,185Jul 01 04:41 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
IBBiShares Biotechnology ETFAUM: 11.36B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B

News

latest 14 of 172
  • Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November (GlobeNewswire)
  • Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM (GlobeNewswire)
  • Lexeo Therapeutics to Participate in the Chardan Healthcare Conference (GlobeNewswire)
  • Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS) (GlobeNewswire) +7.10%
  • Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX for Program Designed to Treat Friedreich Ataxia (PR Newswire) -13.51%
  • Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum (GlobeNewswire)
  • Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia (GlobeNewswire)
  • Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
  • Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)
  • Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy (GlobeNewswire)
  • Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia (GlobeNewswire)
  • Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia (GlobeNewswire) +6.41%
  • Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
  • Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.300-0.285-0.3000.000.0010
2026Q12026-05-11-0.250-0.309-0.2490.000.0010
2025Q42026-03-30-0.270-0.315-0.2740.000.0011
2025Q32025-11-05-0.330-0.520-0.3330.000.009
2025Q22025-08-14-0.600-0.679-0.5990.000.008
2025Q12025-05-12-0.990-0.783-0.9860.000.006
2024Q42025-03-24-0.780-0.807-0.7840.000.007
2024Q32024-11-13-0.890-0.678-0.8920.000.007
2024Q22024-08-12-0.640-0.691-0.6440.000.007
2024Q12024-05-09-0.770-0.738-0.7750.000.005
2023Q42024-03-11-0.860-0.697-0.5330.000.005
2023Q32023-12-11-12.360-0.963-0.7550.000.004
2026Q3---0.322--0.009
2026Q4---0.336--0.009
2027Q1---0.345--0.004
2027Q2---0.350--0.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-12.400-6.662-2.4920.000.00
2024FY-3.090-3.120-3.0930.000.00
2025FY-1.860-1.945-1.8630.000.00
2026FY--1.189--0.00
2027FY--1.336--0.00
2028FY--1.204--46.53
2029FY-0.598--238.46
2030FY-3.272--575.37

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-197000.000.000.00
2026Q3S2026-08-128000.000.000.00
2026Q3S2026-05-138000.000.000.00
2026Q3S2026-05-117000.000.000.00
2026Q3S2026-04-017000.000.000.00
2026Q3S2026-03-316000.000.000.00
2026Q3S2025-12-163000.000.000.00
2026Q3S2025-11-192000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00

Estimate history

EPS, annual-0.193-1.9-2.225-2.492-3.093-1.863-1.1574
Period202020212022202320242025TTM
EPS, quarterly-0.644-0.892-0.784-0.986-0.599-0.333-0.274-0.249-0.302
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.5181.6570.6540000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual26.64626.64626.64626.64633.07173.00178.623
Period202020212022202320242025MRQ
Shares, quarterly33.0433.05833.07133.19253.99854.93473.00174.08778.623
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.651.660.52
Cost of Goods Sold Incl. D&A2.172.082.001.841.150.01-
Gross Profit-2.17-2.08-2.00-1.84-0.491.64-
Selling, General and Administrative Excl. Other92.95107.18103.7666.6760.0252.285.11
Research and Development66.6463.8074.0953.1349.1645.124.32
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-95.12-109.26-105.77-68.51-60.51-50.64-4.59
Interest Expense0.180.210.110.200.09-0.15
Unusual Expense0.000.000.000.530.000.000.42
Net Income Before Taxes-87.27-99.96-98.33-66.39-59.28-50.62-5.15
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-87.27-99.96-98.33-66.39-59.28-50.62-5.15
Net Income From Continuing Operations-87.27-99.96-98.33-66.39-59.28-50.62-5.15
Net Income-87.27-99.96-98.33-66.39-59.28-50.62-5.15
EPS (Recurring)-1.02-1.86-3.09-2.48-2.22-1.90-0.18
EPS (Basic, Before Extraordinaries)-1.16-1.86-3.09-2.49-2.22-1.90-0.19
EPS (Diluted)-1.16-1.86-3.09-2.49-2.22-1.90-0.19
EBITDA-92.95-107.18-103.76-66.67-59.36-50.62-4.59
Non-Operating Income (Expense)8.049.507.552.851.320.020.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense13.8112.1312.473.041.780.39-
Gross Margin-----75.0899.19-
Operating Margin-----9,252.14-3,055.71-884.86
Net Margin-----9,063.76-3,054.80-993.83
Shares Outstanding78.6273.0033.0726.6526.6526.6526.65
Market Capitalization251.19251.19217.57331.05331.05--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.560.550.540.530.510.500.520.51
Gross Profit-0.56-0.55-0.54-0.53-0.51-0.50-0.52-0.51
Selling, General and Administrative Excl. Other27.4621.7922.5821.1230.1833.3026.8631.03
Research and Development19.0315.7016.2115.7014.7217.1718.3723.42
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-28.02-22.33-23.12-21.65-30.69-33.80-27.38-31.54
Interest Expense0.010.020.130.020.030.030.010.04
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-25.87-20.20-20.92-20.28-26.10-32.66-25.92-29.49
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-25.87-20.20-20.92-20.28-26.10-32.66-25.92-29.49
Net Income From Continuing Operations-25.87-20.20-20.92-20.28-26.10-32.66-25.92-29.49
Net Income-25.87-20.20-20.92-20.28-26.10-32.66-25.92-29.49
EPS (Recurring)-0.30-0.25-0.27-0.33-0.60-0.99-0.78-0.89
EPS (Basic, Before Extraordinaries)-0.30-0.25-0.27-0.33-0.60-0.99-0.78-0.89
EPS (Diluted)-0.30-0.25-0.27-0.33-0.60-0.99-0.78-0.89
EBITDA-27.46-21.79-22.58-21.12-30.18-33.30-26.86-31.03
Non-Operating Income (Expense)2.172.152.331.394.611.181.472.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense5.692.752.712.653.073.703.513.79
Shares Outstanding78.6274.0973.0054.9354.0033.1933.0733.06
Market Capitalization251.19418.95724.76358.57133.45115.19217.57298.87

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments181.77121.52121.4777.33135.8629.37
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets6.624.602.832.710.820.03
Total Current Assets188.39126.12124.2980.05136.6829.41
Net Property, Plant & Equipment8.8610.5612.2613.780.170.00
Total Investments and Advances71.4410.263.253.250.000.00
Intangible Assets0.000.000.000.000.00-
Deferred Tax Assets2.442.983.374.23--
Other Assets0.000.000.000.000.000.00
Total Assets271.13149.92143.17101.31136.8629.41
Short Term Debt Incl. Current Port. of LT Debt2.672.672.602.830.000.00
Accounts Payable4.866.423.792.683.060.04
Income Tax Payable--0.160.510.530.04
Other Current Liabilities9.2813.7610.688.333.860.62
Total Current Liabilities16.8122.8517.2414.357.450.70
Long Term Debt5.217.259.0310.650.003.01
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities2.442.983.374.23--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities24.4633.0829.6429.237.453.71
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00185.03185.0131.24
Common Equity246.67116.84113.53-112.95-55.60-5.54
Total Shareholders Equity246.67116.84113.5372.08129.4125.70
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity246.67116.84113.5372.08129.4125.70
Total Liabilities & Stockholders Equity271.13149.92143.17101.31136.8629.41
Book Value Per Share3.383.534.26-4.24-2.09-0.21
Tangible Book Value Per Share3.383.534.26-4.24-2.09-0.21
Full-Time Employees597258-24-
Price to Book Ratio1.021.56-2.20-2.20--
Return on Assets-47.48-67.10-54.31-49.78-60.89-
Return on Equity-55.00-85.37-71.54-58.84-65.27-
Return on Invested Capital-39.69-79.24-54.17-71.65-39.12-17.95
Quick Ratio11.215.527.215.5818.3542.15
Current Ratio11.215.527.215.5818.3542.15

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-87.27-99.96-98.33-66.39-59.28-50.62-5.15
Depreciation2.172.082.001.841.150.01-
Other Funds (Non Cash)13.848.8412.453.571.780.391.87
Funds from Operations-71.26-89.05-83.88-60.98-56.35-50.22-3.28
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-17.11-9.522.731.481.796.040.15
Income Taxes Payable----0.35-0.020.490.04
Cash from Operating Activities-88.37-98.56-81.15-59.50-54.56-44.18-3.13
Capital Expenditures-0.33-0.40-0.48-0.17-0.90-0.190.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments-24.62-89.86-93.600.000.000.000.00
Purchase of Investments-151.99-195.38-93.600.000.000.000.00
Sale Or Maturity of Investments127.36105.530.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-24.95-90.25-94.08-0.17-0.90-0.190.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock171.19217.3389.19100.300.35150.8629.78
Repurchase of Common Pref Stock0.000.00-0.020.000.000.000.00
Sale of Common Pref Stock171.19217.3389.20100.300.35150.8629.78
Proceedsfrom Stock Options168.36137.2788.71100.250.02150.6929.78
Issuance or Reduction of Debt, Net-0.52-0.53-0.413.49-0.160.002.60
Change in Long Term Debt-0.52-0.53-0.413.49-0.160.002.60
Issuance of Long Term Debt0.000.000.004.000.000.002.60
Reduction of Long Term Debt-0.52-0.53-0.41-0.51-0.160.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities170.68216.7988.78103.790.19150.8632.38
Net Change in Cash57.3527.98-86.4544.13-55.27106.4929.25
Free Cash Flow-88.70-98.96-81.63-59.66-55.46-44.37-3.13
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments211.70193.04181.77122.76132.8999.83
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets6.217.826.625.037.175.44
Total Current Assets217.91200.86188.39127.79140.06105.27
Net Property, Plant & Equipment7.888.358.869.419.7610.13
Total Investments and Advances29.1141.1571.446.6426.2510.28
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets--2.44---
Other Assets0.000.000.000.000.000.00
Total Assets254.90250.36271.13143.84176.07125.69
Short Term Debt Incl. Current Port. of LT Debt2.672.692.672.712.662.65
Accounts Payable4.183.334.864.6620.0211.98
Other Current Liabilities8.858.169.289.908.9116.20
Total Current Liabilities15.6914.1916.8117.2731.5930.82
Long Term Debt4.144.675.215.746.266.75
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--2.44---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities19.8418.8624.4623.0137.8537.58
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity235.06231.50246.67120.83138.2288.11
Total Shareholders Equity235.06231.50246.67120.83138.2288.11
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity235.06231.50246.67120.83138.2288.11
Total Liabilities & Stockholders Equity254.90250.36271.13143.84176.07125.69
Book Value Per Share2.993.123.382.202.562.65
Tangible Book Value Per Share2.993.123.382.202.562.65
Full-Time Employees--59---
Price to Book Ratio1.021.704.512.591.510.98
Return on Assets-40.50-46.54-47.48-66.08-62.04-64.51
Return on Equity-46.76-54.75-55.00-80.69-75.32-80.65
Return on Invested Capital-10.81-8.55-8.31-16.02-18.07-34.42
Quick Ratio13.8914.1611.217.404.433.42
Current Ratio13.8914.1611.217.404.433.42

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-25.87-20.20-20.92-20.28-26.10-32.66
Depreciation0.560.550.540.530.510.50
Other Funds (Non Cash)5.712.712.702.71-0.283.71
Funds from Operations-19.60-16.94-17.68-17.04-25.88-28.45
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.00-4.21-2.40-12.51-1.346.73
Cash from Operating Activities-17.60-21.14-20.08-29.55-27.22-21.72
Capital Expenditures-0.01-0.040.00-0.29-0.110.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments14.2727.50-101.6935.30-39.0715.60
Purchase of Investments-11.970.00-140.020.00-55.370.00
Sale Or Maturity of Investments26.2427.5038.3335.3016.3015.60
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities14.2627.46-101.6935.01-39.1715.60
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock24.542.57143.940.1473.080.17
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock24.542.57143.940.1473.080.17
Proceedsfrom Stock Options24.220.12143.920.10-6.920.17
Issuance or Reduction of Debt, Net-0.14-0.12-0.17-0.08-0.12-0.16
Change in Long Term Debt-0.14-0.12-0.17-0.08-0.12-0.16
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.14-0.12-0.17-0.08-0.12-0.16
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities24.402.45143.770.0572.960.01
Net Change in Cash21.078.7722.005.526.57-6.11
Free Cash Flow-17.60-21.18-20.08-29.84-27.33-21.72

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3024.66%17.0M69.1M1.29M
2026-10-1525.41%17.6M69.1M1.24M
2026-09-3027.86%19.2M69.1M1.09M
2026-09-1529.87%20.6M69.1M916.03K
2026-08-3129.66%20.5M69.1M934.72K
2026-08-1429.65%20.5M69.1M941.43K
2026-07-3125.53%17.1M66.8M885.92K
2026-07-1524.48%16.3M66.8M826.72K
2026-06-3024.15%16.1M66.8M904.79K
2026-06-1521.05%14.1M66.9M852.79K
2026-05-2922.34%13.8M61.7M898.50K
2026-05-1521.43%13.2M61.7M874.71K
2026-04-3022.09%13.1M59.1M909.30K
2026-04-1521.79%12.6M57.8M934.44K
2026-03-3120.06%12.5M62.3M1.00M
2026-03-1319.22%11.8M61.4M1.19M
2026-02-2718.13%11.1M61.4M1.17M
2026-02-1318.67%11.5M61.4M1.23M
2026-01-3019.87%12.0M60.3M1.36M
2026-01-1519.01%11.5M60.3M1.44M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.004.904.730.0000.000.000.963-0.0110.000
call2.000.004.903.500.0002.000.000.0000.0000.000
call3.000.000.950.104.9716810.000.824-0.0830.001
call4.000.000.950.106.52282.000.000.598-0.0680.002
call5.000.004.100.107.5221090.000.567-0.0800.002
call6.000.004.100.008.2580.000.000.548-0.0880.002
call7.000.004.100.408.83929.000.000.535-0.0950.002
call8.000.004.100.309.3150.000.000.526-0.1000.002
call9.000.004.100.109.7191.000.000.518-0.1050.002
call10.000.000.100.034.6121880.000.118-0.0230.001
call11.000.004.100.605.1076.000.000.114-0.0270.001
call12.000.004.100.005.3400.000.000.110-0.0270.001
call13.000.004.100.005.4800.000.000.108-0.0270.001
put1.000.004.100.005.1900.000.00-0.036-0.0110.000
put2.000.000.050.050.00063.000.000.0000.0000.000
put3.000.002.350.5015.1801.000.00-0.171-0.0740.001
put4.000.004.900.700.0005.000.00-0.404-0.0660.002
put5.000.104.902.2028.9371580.00-0.433-0.0800.002
put6.000.505.002.5315.19136.000.00-0.452-0.0880.002
put7.001.506.402.9419.40522.000.00-0.465-0.0940.002
put8.002.507.300.0018.7510.000.00-0.474-0.0990.002
put9.003.508.300.0019.1030.000.00-0.482-0.1040.002
put10.004.509.300.0019.4120.000.00-0.883-0.0250.001
put11.005.5010.300.0019.6870.000.00-0.886-0.0250.001
put12.006.9011.500.0022.1430.000.00-0.890-0.0260.001
put13.007.5012.400.0021.1890.000.00-0.892-0.0260.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-04EFFECTEffectiveness filing by commission orderSEC
2026-10-29S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-13SCHEDULE 13GSEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-284Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-228-KCurrent report2026-09-16SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-07SCHEDULE 13GSEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080043.23K3
2026-0700256.58K4
2026-060000
2026-050023.53K2
2026-0400313.14K1
2026-030000
2026-020084.22K2
2026-010000
2025-120000
2025-110024.82K4

Institutional holders

Manager% owned
MONTANOVA CAPITAL, LLC8.13%
Affinity Asset Advisors, LLC7.40%
BlackRock, Inc.7.31%
RA CAPITAL MANAGEMENT, L.P.6.37%
Frazier Life Sciences Management, L.P.6.14%
STATE STREET CORP5.55%
Vestal Point Capital, LP5.50%
Paradigm Biocapital Advisors LP5.32%
Jupiter Topco LLC5.04%
ORBIMED ADVISORS LLC5.03%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.09%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.97%
iShares Russell 2000 ETF2.35%
Fidelity Small Cap Index Fund0.99%
VANGUARD EXTENDED MARKET INDEX FUND0.91%
abrdn Life Sciences Investors0.86%
iShares Russell 2000 Value ETF0.85%
State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF0.72%
Janus Henderson Global Life Sciences Fund0.71%
iShares Biotechnology ETF0.55%

OakChart. LXEO. Cached 15 minutes.